Constitutive Production of Interleukin 6 by Ovarian Cancer Cell Lines and by Primary Ovarian Tumor Cultures

Joanna M. Watson, John L. Sensiintaffar, Jonathan S. Berek, and Otoniel Martínez-Maza

Department of Microbiology and Immunology [J. M. W., O. M.-M.] and Obstetrics and Gynecology [J. L. S., J. S. B., O. M.-M.], and Jonsson Comprehensive Cancer Center, University of California-Los Angeles School of Medicine, Los Angeles, California 90024

ABSTRACT

We examined the production and utilization of interleukin 6 (IL-6), a multifunctional cytokine with diverse biological effects, by both ovarian cancer cell lines and primary ovarian tumor cultures. We have found that epithelial ovarian cancer cell lines (CAOV-3, OVCAR-3, and SKOV-3) constitutively produce varying amounts of IL-6. This molecule is biologically active as determined by the proliferation of an IL-6-dependent hybridoma cell line, MH60.BSF-2, and is detectable by an IL-6 enzyme-linked immunosorbent assay. By cytoplasmic immunoperoxidase staining, >98% of the cells produce at least some IL-6, with variation in the staining intensity between individual cells. The ovarian cancer cell-produced protein has a molecular weight of approximately 24,000, and exhibits some molecular weight heterogeneity, with M, 27,000 and 28,000 minor forms of IL-6. The levels of IL-6 produced by ovarian cancer cells can be modulated by other inflammatory cytokines, such as tumor necrosis factor-α, interleukin-1β, and interferon-γ. Our results suggest that IL-6 is not an autocrine growth factor for these established ovarian tumor cell lines, because the addition of either exogenous IL-6 or antibodies to IL-6 did not affect the cellular proliferation of the cell lines. We also found significant levels (>3 ng/ml) of IL-6 in ascitic fluids of ovarian cancer patients and in the supernatants of primary cultures from freshly excised ovarian tumors. The production of IL-6 by epithelial ovarian cancer cells may prove to be a useful diagnostic tool and aid in investigation of the host immune response to ovarian cancer.

INTRODUCTION

Of all gynecological cancers, ovarian carcinoma has the highest rate of mortality. At the time of diagnosis most patients already present with advanced disease (1). Failure to detect the disease in the early stages results in part from the lack of suitable secreted markers, of which the ovarian tumor-specific marker CA 125 has been the most widely pursued (2). Also, epithelial ovarian cancers are insidious and have a high frequency of subclinical metastasis that frequently remains localized within the peritoneal cavity.

Tumor development has often been associated with either oncogene expression and amplification or inappropriate growth factor regulation. With the exception of the recently identified HER-2/neu oncogene (3), which was found to be overexpressed in approximately 30% of ovarian cancers and was usually indicative of poor clinical prognosis, there has been little success in correlating significant oncogene expression and amplification with ovarian tumors (4). The HER-2/neu oncogene encodes an epidermal growth factor–like receptor (5). Therefore, these findings support the concept that ovarian tumor development and progression are more likely related to inappropriate growth factor regulation. One such factor that offers potential relevance to the progression of ovarian carcinomas is IL-6. Also known as BSF-2, IFN-β2, hybridoma/plasmacytoma growth factor, and M, 26,000 protein (6–9), IL-6 is a pleiotropic cytokine involved in numerous diverse biological functions (10–12). IL-6 has been shown to be produced by tumor cells such as cardiac myoxoma cells (13) and myeloma cells and will in fact augment growth of myeloma cells in an autocrine loop as demonstrated by the growth inhibition of myeloma cells by anti-IL-6 antibodies (14). Recent evidence has shown IL-6 to be produced by both human epidermal cells and epidermoid carcinoma cell lines (15), as well as other epithelium such as bladder carcinoma cells (16) and renal cell carcinoma (17). As the majority of ovarian carcinomas often arise from the coelomic epithelium that covers the ovarian surface (1), we examined the production of IL-6 from several established ovarian carcinoma cell lines (3 of epithelial origin and 1 of germ cell origin) and from freshly excised epithelial ovarian tumors.

In this study we show that 3 of 4 ovarian carcinoma cell lines, as well as primary cultures taken from ovarian tumors, secrete IL-6. By all criteria examined, this IL-6 is indistinguishable from IL-6 produced by other epithelial, lymphoid, or monocyte–toid cell lines. These epithelial ovarian tumor cell lines do not appear to produce IL-6 as an autocrine growth factor. The results of this study will allow further characterization of the role of cytokine production by ovarian tumor cells and provide information on the role of IL-6 as a growth factor for ovarian cancer cells, as well as provide a new potential marker useful in the diagnosis and treatment of ovarian carcinoma.

MATERIALS AND METHODS

Cells. CAOV-3, NIH-OVCAR-3, SKOV-3, and PA-1 are epithelial ovarian cancer cell lines obtained from American Type Culture Collection. Small portions of fresh primary ovarian tumors were minced with sterile scissors in RPMI 1640, the resultant supernatant was seeded into 25cm2 tissue culture flasks (Corning Glass Works, Corning, NY); fed with complete media (RPMI 1640; Whittaker Bioproducts, Inc., Walkersville, MD), 10% FCS (Irvine Scientific, Irvine, CA), 1% L-glutamine, and 1% penicillin/streptomycin (Gibco, BRL, Bethesda, MD); and grown at 37°C with 5% CO2. The cells were washed in PBS and fed prior to reaching confluency (2–3 weeks), and the supernatant was collected 14 days later. Ascitic fluid from ovarian cancer patients was clarified by low-speed centrifugation for 20 min. An aliquot of the supernatant was stored at 4°C until tested for IL-6 activity as described below.

IL-6 Assays. Supernatants were determined to have IL-6 biological activity by bioassay using the IL-6-dependent murine hybridoma cell line MH60.BSF-2 (kindly provided by Drs. T. Kishimoto and T. Hirano, Osaka, Japan) as described previously (18). Briefly, MH60.BSF-2 cells were maintained in RPMI 1640 supplemented with 10% FCS, 1% antibiotics, 1% glutamine, 2% 2-mercaptoethanol, and 5 units/ml rIL-6 (provided by Dr. T. Kishimoto). Duplicate supernatants were serially diluted in 96-well flat-bottomed plates (Nunc, Inc., Roskilde, Denmark). A total of 1 x 104 washed MH60.BSF-2 cells

The abbreviations used are: IL-6, interleukin 6; IFN, interferon; FCS, fetal calf serum; PBS, phosphate-buffered saline; rIL-6, recombinant human interleukin 6; ELISA, enzyme-linked immunosorbent assay; TNF, tumor necrosis factor; IL, interleukin; SDS, sodium dodecyl sulfate; BSF-2, B-cell stimulatory factor-2.
were added per well and the plates were incubated at 37°C for 42 h. At this time, the cells were pulsed with 1 μCi of [3H]thymidine (ICN Biochemicals, Irvine, CA) for 6 h and harvested onto glass membrane filters, and the radioactivity was counted. The concentration of IL-6 that gave 50% maximal proliferation was assigned the value of 0.03 unit/ml. Relative concentration of IL-6 in the culture supernatants was also determined using an IL-6-specific sandwich ELISA (18), which differs from the bioassay by the failure to detect complexed forms of IL-6 (19). This ELISA used a monoclonal anti-human IL-6 primary antibody (kindly provided by Dr. F. Takatsuki, Ajinomoto Co. Inc., Kawasaki, Japan) coated onto plastic 96-well flat-bottomed microplates overnight. Supernatants or rhIL-6 (provided by Dr. T. Kishimoto) standards were added to coated wells, incubated overnight, and then incubated further in the presence of a rabbit anti-IL-6 polyclonal immunoglobulin fraction (Genzyme Corp.). The plates were then incubated with an anti-rabbit horseradish peroxidase-coupled goat serum (Tago, Inc., Burlingame, CA) prior to development with the o-phenylenediamine substrate (Sigma Chemical Co., St. Louis, MO).

Immunoperoxidase Staining for Cytoplasmic IL-6. Ovarian cancer cells cultured on slides were washed in PBS, fixed in precooled acetone for 10 min, and air dried. Prior to staining, cells were washed in PBS for 10 min and incubated with blocking reagent (mouse serum) for 20 min at room temperature. Primary antibody (murine monoclonal anti-IL-6; 80 μg/ml) or isotype control (IgG1) was then added, incubated for 90 min, and washed with PBS for 10 min. After this, the biotinylated antibody (horse anti-mouse IgG) was added, incubated for 30 min, and washed with PBS for 10 min. Following this, the ABC kit (Vector Laboratories, Burlingame, CA) reagents were added according to the manufacturer’s instructions, incubated for 30 min, and washed with PBS for 10 min, and 3-amino-9-ethyl-carbazole substrate solution (freshly prepared) was added and incubated for 10 min with color development checked by light microscopy. The enzyme reaction was stopped with tap water wash to remove substrate.

Neutralization of IL-6 Activity. Fifty μl of culture supernatant collected 5 days postpassage were incubated for 2 h at 37°C in the presence of anti-IL-6 polyclonal antisera (Genzyme) at a final antibody concentration of 0.2, 0.1, or 0.05 μg/μl. The supernatants were further incubated at 4°C until tested in MH60.BSF-2 bioassay as described.

Modulation of IL-6 Secretion by Cytokines. Cells were plated in 96-well flat-bottomed plates at 1–2 x 10³ cells/well to which either TNF-α (Amgen, Thousand Oaks, CA), IL-1β (Amgen), or IFN-γ (Amgen) was added in various concentrations (1–10,000 units/ml final concentration). The final volume was 200 μl/well. The plates were incubated for 48 h at which time the supernatants were removed and tested for IL-6 concentration by ELISA.

IL-6 mRNA Analysis. Isolation and slot-blot analysis of mRNA from the ovarian cancer cell lines were performed as previously described (20) using the guanidium isothiocyanate/cesium chloride ultracentrifugation method (21). The blot was probed with the 32P-labeled 440-base pair Tagl-BantII fragment of BSF-2/IL-6 complementary DNA (pBSF-2.38, kindly provided by Dr. T. Hirano) (22).

Immunoprecipitation and Gel Electrophoresis. To determine the molecular weight of the IL-6 produced by the ovarian cancer cell lines, 10 × 10⁵ cells were plated in the presence of 100 units/ml IL-1β and incubated for 48 h prior to pulsing the cells with 200 μCi of 35S-Trans (ICN Biochemicals) in methionine-deficient RPMI 1640 (ICN Biochemicals), supplemented with 5% FCS for 24 h. The supernatant was incubated overnight at 4°C with anti-IL-6 polyclonal antisera (kindly provided by Dr. F. Takatsuki, Ajinomoto Co. Inc., Kawasaki, Japan) at an antibody dilution of 1:100, followed by a 3-h incubation at room temperature after the addition of 150 μl of a 10% solution of protein A-Sepharose (Pharmacia, Inc., Piscataway, NJ). The beads were washed 5 times in radiimmunoprecipitation assay buffer (0.05 M Tris-HCl, pH 8, 0.1% SDS, 1.0% Triton X-100, 2.0 mM phenylmethylsulfonyl fluoride, 0.15 M NaCl) once in 0.0625 M Tris, pH 6.8, and resuspended in sample buffer (0.125 M Tris, pH 6.8, 4% SDS, 20% glycerol, 10% 2-mercaptoethanol). Antigen-antibody complexes were released from protein A-Sepharose by boiling for 5 min, then incubated on ice for 10 min prior to separation on a 12.5% SDS-polyacrylamide gel. The gel was fixed overnight in 50% ethanol and 7% glacial acetic acid, washed twice in distilled water, incubated for 20 min in 1 M sodium salicylate, and dried prior to autoradiography.

Statistics. Statistical analysis was done by using Student’s t test.

RESULTS

Epithelial Ovarian Cancer Cell Lines Produce IL-6. IL-6 activity in culture supernatants from several well-characterized established ovarian tumor cell lines and supernatants from primary ovarian tumor cells grown in vitro was examined. Culture supernatants from human ovarian cancer cell lines CAOV-3, NIH-OVCAR-3, and SK-OV-3 were found to support the growth of the IL-6-dependent murine hybridoma cell line MH60.BSF-2, indicating the presence of biologically active IL-6 in these supernatants (Fig. 1). This MH60.BSF-2 cell line, with a lower sensitivity limit of 0.03 unit/ml, has been shown to be solely responsive to IL-6; other cytokines, including IL-1α, IL-1β, IL-2-5, IFN-β, IFN-γ, and granulocyte-colony stimulating factor, do not induce cell growth (18). Only PA-1 supernatant failed to produce any detectable IL-6 activity. Preincubation of these culture supernatants with a polyclonal anti-IL-6 antibody significantly reduced the proliferation of the MH60.BSF-2 cells (data not shown). As shown in Table 1 and Figure 1, these supernatants not only produce a molecule that has IL-6 biological activity, but also contain a molecule that
OVARIAN CANCER-PRODUCED IL-6

Table 1 Ovarian cancer cell lines produce IL-6

<table>
<thead>
<tr>
<th>Cell line</th>
<th>IL-6 activity (units/ml)*</th>
<th>IL-6 concentration (ng/ml)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAOV-3</td>
<td>8.4 ± 0.9†</td>
<td>9.1 ± 0.4</td>
</tr>
<tr>
<td>OVCAR-3</td>
<td>0.2 ± 0.02</td>
<td>0.2 ± 0.1</td>
</tr>
<tr>
<td>PA-1</td>
<td>≤ 0.03</td>
<td>≤ 0.05</td>
</tr>
<tr>
<td>SKOV-3</td>
<td>2.5 ± 0.3</td>
<td>2.7 ± 0.5</td>
</tr>
<tr>
<td>Culture medium</td>
<td>≤ 0.03</td>
<td>≤ 0.05</td>
</tr>
</tbody>
</table>

* Results determined by M negative B-SF-2 bioassay.
† Results determined by ELISA.
‡ Mean ± SEM from triplicate experiments using 5-day supernatants harvested from cells plated at 10 x 10⁶ cells/ml.

Table 2 Ovarian cancer cell lines and primary tumor cells stain positive for cytoplasmic IL-6 by immunoperoxidase staining

<table>
<thead>
<tr>
<th></th>
<th>% of positive cells</th>
<th>Staining intensity*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Established lines</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CAOV-3</td>
<td>&gt;98</td>
<td>++/+</td>
</tr>
<tr>
<td>OVCAR-3</td>
<td>&gt;98</td>
<td>++</td>
</tr>
<tr>
<td>PA-1</td>
<td>&gt;75</td>
<td>±</td>
</tr>
<tr>
<td>SKOV-3</td>
<td>&gt;98</td>
<td>++</td>
</tr>
<tr>
<td>Primary tumor cells</td>
<td></td>
<td></td>
</tr>
<tr>
<td>449s</td>
<td>&gt;75</td>
<td>±</td>
</tr>
<tr>
<td>451</td>
<td>&gt;80</td>
<td>±</td>
</tr>
<tr>
<td>453</td>
<td>&gt;80</td>
<td>±</td>
</tr>
<tr>
<td>455</td>
<td>&gt;80</td>
<td>±</td>
</tr>
</tbody>
</table>

* ±, faint, cytoplasmic staining; +, majority of cells lightly stained; ++, areas of dark staining; ++++, areas of intense staining.

Figure 1 shows that 3 of 4 of these ovarian cancer cell lines constitutively exhibit IL-6 activity. The production of this activity is dependent on cell concentration and is linear with time (data not shown). It is interesting to note that the levels of IL-6 produced by each of the cell lines are dramatically different: CAOV-3 produces significantly greater quantities than does SKOV-3, whereas OVCAR-3 produces several-fold less than does SKOV-3 at all times and cell concentrations tested. Increases in the IL-6 levels were noted to coincide with the time the cultures reached confluence, after 72 h for SKOV-3, 5 days for OVCAR-3, and between days 5 and 7 for CAOV-3.

In light of the differences obtained in IL-6 production from plating varying cell concentrations, we sought to determine the relative IL-6 contribution on a per-cell basis using cytoplasmic immunoperoxidase staining. We found that 100% of CAOV-3, SKOV-3, and OVCAR-3 cells are immunoperoxidase-positive using a monoclonal anti-IL-6 antibody (Table 2). There was slight heterogeneity in the intensity of the staining for cytoplasmic IL-6. However, this staining heterogeneity was also seen when the cells were stained for major histocompatibility class I (data not shown). The PA-1 cell line, which failed to secrete IL-6 as determined by bioassay and ELISA of culture supernatants, appeared to be lightly positive for cytoplasmic IL-6. Both ovarian cancer cells isolated from a random selection of solid tumors and ascitic fluids also stained lightly positive for IL-6 in a majority of the cells examined (Table 2).

To confirm that the ovarian cancer cell lines were producing IL-6 without exogenous stimulation, such as endotoxin contamination of the fetal calf serum used to culture the cell lines, we varied the culture conditions and again measured the IL-6 concentration in the supernatants. CAOV-3 produced biologically active IL-6 detectable in all supernatants, including both low serum conditions and Iscoves medium supplemented with albumin and transferrin (Fig. 2), although the level of IL-6 decreased by approximately 75% from 158 units/ml to 39 units/ml. Like CAOV-3, SKOV-3 appears to exhibit a relative or partial dependence upon serum for the production of biologically active IL-6; IL-6 decreased in culture supernatants grown in either 2% FCS by 30% (from 0.57 to 0.41 unit/ml) or by 60% when grown in Iscoves medium supplemented with albumin and transferrin (0.22 unit/ml) as compared with the control. OVCAR-3 produced IL-6 in all media tested, which was at least 90% that of the control (0.49 unit/ml at 5 days). When the cells were also grown in screened FCS-containing medium, IL-6 production was not detected from confluence cultures of each of the cell lines grown in such FCS-supplemented medium as compared with cells grown in medium containing untested FCS: CAOV-3, 6.31 and 7.54 units/ml; OVCAR-3 0.36, 0.48 units/ml; and SKOV-3 1.38, 2.18 units/ml, respectively.

As the production of IL-6 can be induced in different cell types by various different agents, we examined the effects on production of IL-6 by the ovarian cancer cell lines grown in the presence of other inflammatory cytokines, TNF-α, IL-1β, and IFN-γ. IL-6 production by CAOV-3 was found to be enhanced (P < 0.01) in the presence of either TNF-α (all concentrations) or IFN-γ (100 units/ml), while being unaffected by the presence of IL-1β (Table 3). OVCAR-3 modulated IL-6 production in a vigorous dose-dependent fashion to IL-1β (P < 0.005 at >10 units/ml), with a significant response to TNF-α (P < 0.01) and a negligible response to IFN-γ (Table 2). SKOV-3 showed dose-dependent modulation of IL-6 production by all 3 cytokines tested with significant increases in IL-6 production seen at the highest doses used (P < 0.01). The most dramatic enhancement of IL-6 secretion by SKOV-3 was induced by 100 units/ml of IL-1β where the IL-6 level increased 10-fold over the control level (Table 3). Neither TNF-α, IL-1β, nor IFN-γ was capable of stimulating production of IL-6 from PA-1 (data not shown).

Fibroblasts and monocytes have been shown to produce multiple forms of IL-6 (23). To determine what molecular weight form(s) of IL-6 were being synthesized and secreted by these ovarian cancer cell lines, we immunoprecipitated IL-6 from the culture supernatants of metabolically labeled cells. It appears that the IL-6-producing lines all secrete a major species of IL-6 that shares antigenic reactivity with human IL-6 as detected in an IL-6 ELISA (sensitive to 0.05 ng/ml). The media preparation alone failed to support the growth of the MH60.BSF-2 hybridoma cells (Table 1), indicating that the media itself did not contain any IL-6 activity.
6 that has a molecular weight of 24,000 (Fig. 3A). CAOV-3 also secretes isoforms of IL-6 at M, 27,000 and 28,000. This heterogeneity has been seen with other epidermal cells and epidermoid carcinoma cell lines (15). It is possible that OVCAR-3 and SKOV-3 also secrete other forms of IL-6 but in concentrations too low to be detected by immunoprecipitation. As a control, IL-6 was immunoprecipitated from the supernatants both from a human monocytic cell line (THP-1) and from lipopolysaccharide-activated peripheral blood mononuclear cells (Fig. 3B). The major species immunoprecipitated with this antibody is M, 24,000, with minor species of protein detectable at slightly higher molecular weights.

Slot-blot RNA analysis revealed the presence of IL-6-specific mRNA in SKOV-3 and CAOV-3 cell lines but failed to detect OVCAR-3 and PA-1 mRNA specific for IL-6 (Fig. 4). The levels of mRNA do not appear to directly correlate with the relative protein activity detectable in the culture supernatants because CAOV-3, which secretes more IL-6 protein than SKOV-3, has less specific mRNA than SKOV-3. The cause of this variation is unknown but could be the result of either greater mRNA stability or translation efficiency in the CAOV-3 cell line as opposed to the SKOV-3 line. Precedent for detection of a biologically active protein and subsequent failure to detect associated mRNA, as in the case of OVCAR-3, which secretes more IL-6 protein than SKOV-3, has been demonstrated. Ramakrishnan et al. (24) have shown detectable macrophage-colony stimulating factor activity in culture supernatants of ovarian cancer cell lines, including OVCAR-3, while failing to detect corresponding specific cytokine mRNA.

**IL-6 Production by Freshly Isolated Ovarian Cancer Cells.** Since ovarian cancer cell lines represent fully transformed cells that have been selected for their ability to grow in vitro, the unstimulated constitutive production of IL-6 by these cell lines may be a consequence of such selection. To determine the relevance of ovarian cancer cell line-produced IL-6 to an in vivo condition, we examined freshly isolated ovarian tumors for the production of IL-6. In this study, all primary culture supernatants (n = 19) from freshly excised ovarian tumors and all ovarian cancer patient ascitic fluids (n = 24) were found to have detectable IL-6 levels (Table 4). The concentration ranged from 3 to 40 ng/ml and was detectable in both the IL-6 ELISA and MH60.BSF-2 bioassay (data not shown). The high (>3 ng/ml) IL-6 activity in all ascitic fluids (n = 24) tested cannot be directly linked to IL-6 produced by ovarian tumor cells. Ascitic fluid, obtained from one patient with a gynecological condition other than ovarian cancer, was found to have an IL-6 level of <3 ng/ml (1.8 ng/ml). Peritoneal fluid obtained from healthy women undergoing voluntary tubal ligations (n = 7) was found to contain IL-6 levels comparable with that of the non-cancer patient (2.1 ng/ml).

**IL-6 is Not an Autocrine Growth Factor for Epithelial Ovarian Cancer Cells.** To determine whether IL-6 is an autocrine growth factor for ovarian cancer cells, we examined the cellular proliferative response of the ovarian cancer cells in the presence of either exogenous rhIL-6 over a range of concentrations (0.01

### Table 3 Modulation of IL-6 secretion from ovarian cancer cells by TNF-α, IL-1β, and IFN-γ

<table>
<thead>
<tr>
<th></th>
<th>CAOV-3 cell line</th>
<th>OVCAR-3 cell line</th>
<th>SKOV-3 cell line</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>35.3 ± 0.7</td>
<td>0.1 ± 0.03</td>
<td>0.6 ± 0.4</td>
</tr>
<tr>
<td>TNF-α</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10 units/ml</td>
<td>51.4 ± 0.1</td>
<td>0.3 ± 0.09</td>
<td>1.00 ± 0.00</td>
</tr>
<tr>
<td>100 units/ml</td>
<td>54.9 ± 3.0</td>
<td>0.9 ± 0.2</td>
<td>1.7 ± 0.2</td>
</tr>
<tr>
<td>1,000 units/ml</td>
<td>52.1 ± 1.9</td>
<td>0.8 ± 0.3</td>
<td>2.8 ± 0.2</td>
</tr>
<tr>
<td>IL-1β</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 unit/ml</td>
<td>35.0 ± 0.3</td>
<td>0.04 ± 0.0</td>
<td>0.5 ± 0.4</td>
</tr>
<tr>
<td>10 units/ml</td>
<td>37.2 ± 9.3</td>
<td>1.1 ± 0.07</td>
<td>1.7 ± 0.5</td>
</tr>
<tr>
<td>100 units/ml</td>
<td>33.4 ± 1.2</td>
<td>10.3 ± 1.3</td>
<td>6.2 ± 1.8</td>
</tr>
<tr>
<td>IFN-γ</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 unit/ml</td>
<td>45.6 ± 10.6</td>
<td>0.1 ± 0.02</td>
<td>0.9 ± 0.04</td>
</tr>
<tr>
<td>100 units/ml</td>
<td>50.6 ± 6.7</td>
<td>0.1 ± 0.05</td>
<td>1.4 ± 0.05</td>
</tr>
<tr>
<td>1,000 units/ml</td>
<td>52.8 ± 1.7</td>
<td>0.1 ± 0.03</td>
<td>1.5 ± 0.06</td>
</tr>
</tbody>
</table>

*Mean ± SD of triplicate samples from one representative experiment (n = 4).*

**Fig. 3.** Immunoprecipitation of IL-6 from culture supernatants of epithelial ovarian cancer cell lines reveals a M, 24,000 protein. Supernatants from cells incubated in the presence of 100 units/ml IL-1β were metabolically labeled with [35S]-Trans for 24 h and immunoprecipitated with a polyclonal antiserum for IL-6 (1:100 final dilution). Immunoprecipitates were separated on a 12.5% SDS-polyacrylamide gel electrophoresis, dried, and autoradiographed for 3 days. A, Lanes 1 and 2, immunoprecipitate from CAOV-3 supernatant; Lanes 3 and 4, from OVCAR-3; Lanes 5 and 6, from PA-1; Lanes 7 and 8, from SKOV-3; Lanes 9 and 10, from primary culture 436; Lanes 11–14, from the monocytic line THP-1, representing supernatants from unstimulated cells, LPS- and IFN-γ-stimulated cells, and stimulated cells plus excess of cold IL-6, respectively. Lanes 2, 4, 6, 8, 10, and 14 are immunoprecipitates from supernatants treated with pre-immune rabbit antisera. B, Lanes 1–5, immunoprecipitates from peripheral blood mononuclear cells. Lane 1 from unstimulated cells; Lanes 2–5, peripheral blood mononuclear cells were stimulated with 1 μg/ml lipopolysaccharide and immunoprecipitated with Ajinomoto antisera (Lanes 2 and 4) or Genzyme polyclonal anti-IL-6 (Lane 3); Lane 4 supernatant was pretreated with cold IL-6 prior to immunoprecipitation; Lane 5 immunoprecipitate with preimmune rabbit antisera. Molecular weight markers are indicated in thousands.
constitutively produce a molecule with the biological and antigenic characteristics of IL-6. SKOV-3 and CAOV-3 are cell lines that constitutively produce moderate to high levels of IL-6 and detectable IL-6 mRNA. OVCAR-3 produces low amounts of IL-6 (<0.5 unit/ml) even at culture confluency and has no detectable IL-6 mRNA. The IL-6 produced by these ovarian cancer cell lines has a molecular weight of approximately 24,000, and exhibits some of the molecular weight heterogeneity often associated with IL-6 produced by epithelial cells (15).

Significant levels (>3 ng/ml) of IL-6 activity were also detected in the supernatants of primary ovarian tumor cultures and in ovarian cancer patient ascitic fluid. Although every effort was made to ensure that there were no contaminating peritoneal monocyte/macrophage cells in the cultures, the possibility of such cells contributing to IL-6 production cannot be excluded. However, by nonspecific esterase staining of a random selection of the primary cultures, we found that there was <10% macrophage contamination in these cultures (data not shown), whereas the cultures stained for cytoplasmic IL-6 by the immunoperoxidase technique expressed >75–80% IL-6 reactivity. The levels of IL-6 in the primary tumor cultures are significant in that tumor cells are exposed to no additional stimulus other than being placed in culture and go through changes in culture medium prior to testing the supernatant, removing any IL-6 secreted by contaminating monocytes upon adherence to the tissue culture flask.

In this study, we emphasize the production of IL-6 from the tumor cells themselves, unlike Erroi et al. (25), who have reported that IL-6 is constitutively produced by tumor-associated macrophages in ovarian carcinomas, without significant contribution from the neoplastic elements. Differences in isolation procedures and cell line selections probably account for the variation between their reported results and ours. However, the original source from which their cell lines were derived is not stated, and as shown here, cell lines from germ cell tissue (PA-1) did not secrete IL-6, whereas those of epithelial origin (CAOV-3, OVCAR-3, and SKOV-3) were seen to produce and secrete IL-6. Our results support those of Tabibzadeh et al. (26), who examined IL-6 immunoreactivity in human tumors by immunohistological staining and found that the majority of human tumors of epithelial or mesenchymal origin stain positive for IL-6. From such immunohistological procedures it was not apparent whether the tumors actually produced IL-6 or simply utilized and stored IL-6 produced by other cells. Our results suggest that the neoplastic elements themselves produce IL-6.

The source of the activity detected in the ascites fluids cannot be ascribed to IL-6 solely produced by the ovarian tumors. Despite the uncertain source of the ascitic fluid IL-6, it is apparent that there are extremely high levels of this cytokine within the peritoneal cavity of patients with ovarian cancer. Because the accumulation of ascitic fluid is an abnormal condition per se, the appropriate control for examining ascitic fluid IL-6 levels would be ascitic fluid from women with gynecological conditions other than ovarian carcinoma. Interestingly, the one such fluid tested contained only low levels (<3 ng/ml) of detectable IL-6, comparable with that found in peritoneal fluid from healthy women undergoing voluntary tubal ligations. The high concentrations of IL-6 within a confined and localized region reported here are not unique because high levels (>1000 units) of IL-6 have been reported to be present in amniotic fluid (27), in the synovial fluid of rheumatoid arthritis patients (28), and in localized regions of acute bacterial infections (29). These

### DISCUSSION

Here we report that 3 well-characterized human ovarian carcinoma cell lines, CAOV-3, NIH-OVCAR-3, and SKOV-3,
high levels of IL-6 do not appear to directly contribute to the
immunosuppressive effects of ascitic fluid (30) because neutral-
ization of the IL-6 in the ascitic fluid was not capable of
restoring proliferation to phagohagglutin-stimulated pe-
ripheral blood mononuclear cells (data not shown). It remains
to be determined what immune function IL-6 plays in such
localized regions, and whether in high, sustained concentrations
IL-6 actively suppresses or enhances other immune functions
or induces a state of nonresponsiveness through indirect means.

Although IL-6 has been implicated as an autocrine growth
factor in other tumors (14), the results presented here showing
that the levels of IL-6 continue to rise even after the cultures
have reached confluency, the lack of proliferative inhibition in
the presence of antibodies, and the lack of proliferative response
to exogenous IL-6 suggest that these ovarian carcinoma cell
lines are not producing this cytokine as an autocrine growth
factor. Recent evidence from Klein et al. (31) suggested that
IL-6 regulated myeloma cell growth by a paracrine (as opposed
to an autocrine) mechanism (14). The possible role of ovarian
cell-produced IL-6 as an exocrine or paracrine growth factor
for other cells of the peritoneal cavity is intriguing, especially
if considered in light of the high levels of the cytokine that are
produced and retained within the peritoneal cavity and the lack
of metastasis outside of the cavity. It has been proposed by
Tamm et al. (32) that IL-6 may aid in tumor metastasis and
invasiveness, since exogenous IL-6 was shown to increase mo-
tility and decrease adhering-type junctions in the breast carci-
noma cell lines T47D and Zr-75-1. It is not known whether
autonomously produced IL-6 would affect the motility and
adherence of the ovarian cancer cell lines, but this could provide
an explanation for the high degree of local seeding that occurs
throughout the peritoneal cavity in patients with ovarian carci-
noma.

All the primary ovarian tumors and ovarian cell lines that
produced IL-6 activity were classified as adenocarcinoma tu-
mors. The single ovarian carcinoma cell line that failed to
produce any IL-6, PA-1, was originally derived from a terato-
carcinoma (33). This germ cell tumor is derived from undiffer-
entiated cells exhibiting characteristics of embryonal carcinoma
cells, as opposed to the adenocarcinomas, which characteristi-
cally contain more differentiated cells. The relevance of the
state of differentiation to IL-6 production cannot be drawn
from this study. However, it would be interesting to examine
this further to determine if such a correlation exists, since this
may provide a useful diagnostic tool. The ovarian carcinoma
marker CA 125 has been demonstrated to be associated with
approximately 85% of serous ovarian tumors and 70% of
undifferentiated tumors, and only rarely with mucinous tumors
(2). Likewise there has been some association between other
markers such as CEA and CA 19-9 and other types of ovarian
carcinoma (mucinous and endometroid). However, none of
these particular tumor markers shows specificity for cancer or
correlates with their respective secreted marker serum values.
Studies to examine circulating serum IL-6 levels in ovarian
cancer patients are currently underway. If a correlation is
found between circulating IL-6 levels and ovarian tumor status, IL-6
may prove useful as another marker for ovarian cancer.

Evidence from Boltz et al. (4), regarding the lack of any
significant amplification of the c-ras-Ki oncogene in ovarian
tumors, and the results of this study suggest that ovarian tumor
progression may be related to abnormal growth factor regula-
tion as opposed to inappropriate oncogene expression and
amplification. Evidence relating abnormal growth factor regu-
lation to ovarian tumor progression has been demonstrated by
the amplification and overexpression (3) of an epidermal
growth factor-like receptor (5) encoded by the HER-2/neu
oncogene. In further support of this idea, we have shown here
that 2 of the IL-6-producing cell lines (CAOV-3 and SKOV-3)
constitutively express IL-6 mRNA. Although the overexpression
of IL-6 has been implicated in the pathogenesis of numer-
ous diseases, including some lymphoid cancers (34), it remains
to be determined what role such deregulated expression of IL-
6 has in the development and progression of ovarian cancer.

ACKNOWLEDGMENTS

The authors would like to thank Reba Knox, Meta Vander Meyden,
and Ahmad Rezai for their assistance with the IL-6 ELISA, immuno-
peroxidase staining, and RNA analysis; Drs. Tadamitsu Kishimoto
and Toshio Hirano of Osaka University, Osaka, Japan, for providing
IL-6, IL-6 complementary DNA, and the IL-6-responsive cell line,
MH60.BSF-2; Dr. Fumihiko Takatsuki of Ajinomoto Co., Inc., Ka-
wasaki, Japan, for providing polyclonal and monoclonal antibodies
to IL-6; and Dr. Donna Vredevoe for the use of laboratory facilities.

REFERENCES

1. Berek, J. S. Epithelial ovarian cancer. In J. S. Berek and N. F. Hacker (eds.),
Practical Gynecologic Oncology, pp. 327–371. Baltimore: Williams & Wil-
kins, 1989.

2. Neutenfeld, W., and Breitenecker, G. Tissue expression of CA 125 in benign
and malignant lesions of ovary and fallopian tube: a comparison with CA

Studies of HER-2/neu proto-oncogene in human breast and ovarian cancer.

M. L. Amplification of c-ras-Ki oncogene in human ovarian tumors. Int. J.

5. Kokai, Y., Dobashi, K., Weiner, D. B., Myers, J. N., Nowell, P. C., and
Greene, M. L. Phosphorylation process induced by epidermal growth factor
alters the oncogenic and cellular new (NGL) gene products. Proc. Natl.

6. Hirano, T., Taga, T., Nakano, N., Yasukawa, K., Kashiwamur, S., Shimizu,
K., Nakajima, K., Pyun, K. H., and Kishimto, T. Purification to homoge-
neity and characterization of human B-cell differentiation factor (BCDF or

7. Zilberstein, A., Ruggieri, R., Korn, J. H., and Revel, M. Structure and
expression of cDNA and genes for human interferon-^7-8, a distinct species

8. Van Damme, J., Opdenakker, G., Simpson, R. J., Rubira, M. R., Cyphas,
S., Vink, A., Billau, A., and Van Snick, J. Identification of the human 26-
KDa protein, interferon â (IFN-â), as a B cell hybridoma/plasmacytoma
growth factor induced by interleukin 1 and tumor necrosis factor. J. Exp.

9. Poupard, P., Vandenebelle, P., Cyphas, S., Van Snick, J., Hageman, G.,
Kruys, V., Fiers, W., and Content, J. B cell growth modulating and differ-
entiating activity of recombinant human 26-KDa protein (BSF-2, HulFN-â,

10. Hirano, T., Yasukawa, K., Harada, H., Taga, T., Watanabe, Y., Matsuda,
T., Kashiwamur, S., Nakajima, K., Koyama, K., Iwamatsu, A., Tsunasawa,
S., Sakiyama, F., Matsui, H., Takahara, Y., Taniguchi, T., and Kishimoto,
T. Complementary DNA for a novel human interleukin (BSF-2) that induces
B lymphocytes to produce immunoglobulin. Nature (Lond.), 324: 73–76,
1986.

Interferon â/2/B-cell stimulatory factor type 2 shares identity with monocyte-
derivate hepatic substance stimulating factor and regulates the major acute phase
protein response in liver cells. Proc. Natl. Acad. Sci. USA, 84: 7251–7255,
1987.

stimulating factor 2 (âIFN-â) functions as a second signal for interleukin
2 production by mature murine T cells. Proc. Natl. Acad. Sci. USA, 84:

13. Hirano, T., Taga, T., Yasukawa, K., Nakajima, K., Nakano, N., Takatsuki,
F., Shimizu, M., Murashimo, A., Tsunasawa, S., Sakiyama, F., and Kishimto,
T. Human B cell differentiation factor defined by an antipeptide antibody

14. Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku,
H., Tanga, T., Tanabe, O., Tanaka, H., Kuramoto, A., and Kishimoto, T.
Autocrine generation and requirement of BSF-2/IL-6 for human multiple


Constitutive Production of Interleukin 6 by Ovarian Cancer Cell Lines and by Primary Ovarian Tumor Cultures
